Lovisa Afzelius

Lovisa Afzelius has a diverse and extensive work experience in the biotechnology and pharmaceutical industries. Starting in 2013 with Pfizer, they held various roles including Senior Director in Immunoscience RU, Head of Computational Precision Medicine, and Executive Director leading Systems Immunology. In 2017, they joined Repertoire Immune Medicines as a Senior Vice President. Lovisa also co-founded and served as a Board Member and Chairman of the Board at Elsa Science. In 2020, they became the President of Generate Biomedicines and also held leadership positions at Flagship Pioneering, Alltrna, and Apriori Bio as an Origination Partner, Founding CEO & Director, and Co-founder & CEO, respectively. In 2021, they co-founded Metaphore Biotechnologies and in 2022 they co-founded FL89. Additionally, Lovisa Afzelius has served on the Board of Directors for the Swedish American Chamber of Commerce - New England.

Lovisa Afzelius pursued their education in a diverse range of fields. Lovisa began their academic journey by completing a Master of Science degree at the University of Gothenburg between 1995 and 2000. The specific degree and field of study for their MSc are not mentioned. Following this, they enrolled at the University of Uppsala from 2001 to 2004, where they pursued a Doctoral degree in Computational Chemistry. Lastly, Lovisa attended the prestigious MIT Sloan School of Management from 2014 to 2016, where they obtained an Executive MBA, specializing in Master of Business Administration.